| ★ | Diabetes Dialogue: Retatrutide Phase 3 Data Show Major Weight Loss | | 533 | Estados Unidos | |
| 16 | Retatrutide Just Broke Every Obesity Record | Dr Brad Stanfield @drbradstanfield | 57.0K | Nueva Zelanda | 90 |
| 12 | Diabetes Dialogue: Omnipod and AID Advancements at Insulet, With Trang Ly, PhD, MBBS | | 4.3K | Estados Unidos | 90 |
| 13 | Unlocking Weight Loss Secrets No Plateaus, Diabetes Reversed! #weightloss #retatrutide #glp1 | Dr. G's Lifestyle Medicine Network @gooddrg | 2.8K | Estados Unidos | 90 |
| 3 | Retatrutide Provides Substantial Weight Loss in Patients With Obesity or Overweight | | 1.1K | Estados Unidos | 96 |
| 9 | Retatrutide (The Next Generation GLP 1 Drug) | Dr. Marc Morris @drmarcmorris | 958 | Canadá | 91 |
| 15 | Diabetes Dialogue: The ADA’s Statement on Diabetes Tech Integration, With Eugene Wright Jr., MD | | 584 | Estados Unidos | 90 |
| 2 | TRIUMPH-2: Retatrutide Reduces Weight, A1C in Patients With Obesity | | 350 | Estados Unidos | 97 |
| 11 | Diabetes Dialogue: Weekly Insulin Icodec Now Available for Type 2 Diabetes | | 206 | Estados Unidos | 91 |
| 7 | Diabetes Dialogue: CKM Systems, Triple Agonists, and a Sensor Scandal Ahead of ADA | | 179 | Estados Unidos | 91 |
| 18 | SYNCHRONIZE-1: Survodutide Achieves Significant Weight Loss Versus Placebo | | 174 | Estados Unidos | 90 |
| 6 | Rapid Evolution in GLP-1s and Therapeutics at ADA 2026 | | 171 | Estados Unidos | 92 |
| 1 | Retatrutide Cuts Weight, Cardiovascular Disease Risk in TRIUMPH-3 | | 158 | Estados Unidos | 98 |
| 10 | Diabetes Dialogue: Tegoprubart and Freedom from Insulin in Type 1 Diabetes | | 143 | Estados Unidos | 91 |
| 4 | Diabetes Dialogue: CONNECT, TRANSCEND, and TRIUMPH at ADA 2026 | | 114 | Estados Unidos | 93 |
| 17 | Diabetes Dialogue: Diabetes Technology and Treatment in the UK, With Ketan Dhatariya, MD, PhD, MS | | 94 | Estados Unidos | 90 |
| 14 | Diabetes Dialogue: The International Diabetes Federation and Care in India, With Amit Gupta, MBBS | | 79 | Estados Unidos | 90 |
| 5 | Incretins, Monitors, and Insulin Titration at ADA 2026 | | 76 | Estados Unidos | 93 |
| 8 | Diabetes Dialogue: Signos and the Science of Weight Loss | | 75 | Estados Unidos | 91 |
| 19 | Secret Shopper Study Reveals GLP-1 Telehealth Gaps | | 70 | Estados Unidos | 90 |
| 20 | Diabetes Dialogue: Teplizumab, Stelo, and Inhaled Insulin Afrezza for Pediatric Patients | | 53 | Estados Unidos | 90 |